Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Non-ST Elevation MI: How Long Do We Have for A Coronary Angiography?

This summary discusses the early invasive strategy and the risk of mortality in non-ST-elevation AMI.


Over the past 2 decades, mortality and complications rates have seen a significant reduction thanks to technological and pharmaceutical development, and the increasing experience of health teams. This is especially true when we look at the use of coronary angiography withing 72 hours of symptom onset; in these cases, mortality risk has gone from 3 to 6 months. 

IAM sin elevación del ST: ¿cuánto tiempo tenemos para realizar una coronariografía?

At present, the information is contradicting when it comes to an early invasive strategy. Even though some registries and randomized studies have not shown improvement, this might be the result of different factors, such as the time between symptom onset and the coronary angiography. 

The KAMIR-NIH with 5856 non-ST myocardial infarction patients (NSTEMI) was analyzed: 3919 of these patients had a symptom onset to catheter time (StC) of <48 hours (66.9%) and 1937 a >48-hr StC.

Primary end point was all cause mortality at 3 years and secondary end point was the composite of all cause death, repeat MI or rehospitalization for cardiac failure at 3 years. 

Mean age was 64 and over 70% were men. 

Read also: Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients presenting <48 hr. StC more often presented hypertension, diabetes, kidney function deterioration, MI, typical angina, angina after the first episode, less cardiac failure, lower GRACE score and better left ventricular function. 

StC was 17.5 hrs. vs 90.8 hrs.

The presence of left main severe stenosis was 5.6%, 3 vessel disease 19%, 2 vessel lesion 28% and one vessel lesion 45%. PCI was done in 85% of cases, CABG in 1.5% and the rest received optimal medical treatment.   

Primary end point at 3 years was 7.3% vs. 13.4% (3-year adjusted HR: 0.76; 95% CI:0.64-0.91; P = 0.002) for <48 hr. StC patient vs >48 hr StC patients respectively. Secondary end point was also in favor of <48 hr StC (12.2% vs. 19.6% 3-year adjusted HR: 0.84; 95% CI: 0.73-0.96; P=0.015).

Read also: Is it Possible to Reduce DAPT Time in Diabetic Patients?

The use of emergency systems was associated to <48 hr StC and lower mortality.

Conclusion

An early invasive strategy based on symptom to catheter time was associated to lower all-cause mortality risk in NSTEMI patients. Seeing as this is a prospective registry, this conclusion should be considered as hypothesis generator to encourage future research. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Early Invasive Strategy Based on the Time of Symptom Onset of Non-ST-Segment Elevation Myocardial Infarction.

Reference: SungA Bae, et al. J Am Coll Cardiol Intv 2023;16:64–75.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...